The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0273839
Abstract: Purpose To evaluate the prognostic value of pretreatment 18F-FDG PET/CT after consolidation therapy of 131I-rituximab in patients with diffuse large B-cell lymphoma (DLBCL) who had acquired complete remission after receiving chemotherapy. Methods Patients who were… read more here.
Keywords: 18f fdg; 131i rituximab; consolidation therapy; fdg pet ... See more keywords
Camptothecin enhances 131I-rituximab-induced G1-arrest and apoptosis in Burkitt lymphoma cells
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/jcrt.jcrt_1012_19
Abstract: Background: Rituximab is a chimeric monoclonal antibody against CD20. It is an established immunotherapeutic agent for non-Hodgkin's lymphoma. Even though rituximab has been used in clinics for decades, only 50% of the patients respond to… read more here.
Keywords: rituximab; 131i rituximab; apoptosis; raji cells ... See more keywords